Provided by Tiger Trade Technology Pte. Ltd.

Milliman Healthcare Inflation Plus ETF

20.52
+0.04040.20%
Post-market: 20.520.00000.00%16:10 EDT
Volume:14
Turnover:289
Market Cap:1.54M
PE:- -
High:20.52
Open:20.48
Low:20.52
Close:20.48
52wk High:21.40
52wk Low:19.45
Shares:75.00K
Float Shares:75.00K
Volume Ratio:0.49
T/O Rate:0.02%
Dividend:- -
Dividend Rate:- -
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Roche, Eli Lilly's Alzheimer's Blood Test Gets FDA Clearance

Reuters
·
Aug 24

Barclays Sticks to Its Buy Rating for Eli Lilly & Co (LLY)

TIPRANKS
·
Aug 24

Eli Lilly: Working with Nice on Assessment of Foundayo for Potential Use on Nhs in England

THOMSON REUTERS
·
Aug 24

Eli Lilly Launches Oral Weight-Loss Pill Foundayo in UK

Reuters
·
Aug 24

Eli Lilly: Foundayo NOW Available in UK to be Prescribed for Eligible Adults Via Private Prescription

THOMSON REUTERS
·
Aug 24

Eli Lilly: in UK, Foundayo is Priced Lower than Mounjaro; Likely to be in Order of £100 to £120

THOMSON REUTERS
·
Aug 24

UnitedHealth Group (UNH) Joins Zacks Strong Buy List As Undervalued Narrative Builds

Simply Wall St.
·
Aug 23

Soon You Can Buy Medicare Advantage Plans at Costco. What You Need to Know.

Dow Jones
·
Aug 22

UnitedHealth Group (UNH) Stock Looks Cheap On Value But Faces Risk On News

Simply Wall St.
·
Aug 22

Eli Lilly Targets Ramadan Diabetes Market With New Orforglipron Trial

TIPRANKS
·
Aug 22

Eli Lilly’s Dulaglutide Study Sheds Light on Fasting Risks and Diabetes Care

TIPRANKS
·
Aug 22

Pharma Stocks Have Rallied. 2 Stocks to Avoid-and 2 to Buy.

Dow Jones
·
Aug 21

Eli Lilly Advances Early-Stage Eloralintide Trial: What Investors Should Watch

TIPRANKS
·
Aug 21

Eli Lilly’s Lebrikizumab Trial Completion Signals New Growth Path in Atopic Dermatitis

TIPRANKS
·
Aug 21

Eli Lilly Revenue Jumps 48% as Mounjaro and Zepbound Sales Reach $14.9B

TradingKey
·
Aug 20

Pharma Sector Doubles Down on AI Amid Hopes of Slashing Costs, Timelines

Reuters
·
Aug 20

7 Growth Stocks Holding up in a Tough Market

Dow Jones
·
Aug 20

Will Foundayo’s UK GLP‑1 Approval and New R&D Deals Change Eli Lilly's (LLY) Narrative?

Simply Wall St.
·
Aug 20

Amplitude Therapeutics: Lilly to GET Exclusive, Target-Specific Rights to Develop ,Commercialize Licensed Products Directed to Collaboration Targets

THOMSON REUTERS
·
Aug 20

Amplitude Therapeutics and Lilly Enter Strategic Collaboration to Develop Trans-Amplifying Rna Vaccines for Infectious Diseases

THOMSON REUTERS
·
Aug 20